Immunotherapy Research Funded

Home page Description: 
Terry Fox Foundation/CIHR support cancer immunotherapy projects led by Drs. Ohashi and Lupien.
Posted On: October 19, 2016
Image Caption: 
As one of two UHN researchers that received funding, Dr. Pamela Ohashi (pictured) is leading a pan-Canadian immunotherapy research network.
Two projects, led by UHN researchers Dr. Pamela Ohashi and Dr. Mathieu Lupien, were selected for funding by the Terry Fox Research Institute. Dr. Ohashi will receive $5.41M over five years and Dr. Lupien will receive $2.25M over three years to advance their investigations into the use of cancer immunotherapy—a strategy that uses the body’s immune system to kill cancer cells.
 
Dr. Pamela Ohashi is the Director of UHN’s Tumour Immunotherapy Program and a Senior Scientist at PM Cancer Centre. Her project will develop and evaluate new immunotherapies for high grade serous ovarian cancer—the deadliest type of ovarian cancer.
 
Dr. Mathieu Lupien is a Senior Scientist at the PM Cancer Centre. His project will focus on advancing immunotherapy for women with triple negative breast cancer, a type of cancer that tends to have lower survival and higher recurrence rates.
 
A total of six projects were funded nationwide that amounted to $27.3M. The awards were supported by the Terry Fox Foundation, which hosts the annual Terry Fox Run, and the Canadian Institutes of Health Research. For more information, see the press release.